<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36309735</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Synaptic proteomics reveal distinct molecular signatures of cognitive change and C9ORF72 repeat expansion in the human ALS cortex.</ArticleTitle><Pagination><StartPage>156</StartPage><MedlinePgn>156</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">156</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-022-01455-z</ELocationID><Abstract><AbstractText>Increasing evidence suggests synaptic dysfunction is a central and possibly triggering factor in Amyotrophic Lateral Sclerosis (ALS). Despite this, we still know very little about the molecular profile of an ALS synapse. To address this gap, we designed a synaptic proteomics experiment to perform an unbiased assessment of the synaptic proteome in the ALS brain. We isolated synaptoneurosomes from fresh-frozen post-mortem human cortex (11 controls and 18 ALS) and stratified the ALS group based on cognitive profile (Edinburgh Cognitive and Behavioural ALS Screen (ECAS score)) and presence of a C9ORF72 hexanucleotide repeat expansion (C9ORF72-RE). This allowed us to assess regional differences and the impact of phenotype and genotype on the synaptic proteome, using Tandem Mass Tagging-based proteomics. We identified over 6000 proteins in our synaptoneurosomes and using robust bioinformatics analysis we validated the strong enrichment of synapses. We found more than 30 ALS-associated proteins in synaptoneurosomes, including TDP-43, FUS, SOD1 and C9ORF72. We identified almost 500 proteins with altered expression levels in ALS, with region-specific changes highlighting proteins and pathways with intriguing links to neurophysiology and pathology. Stratifying the ALS cohort by cognitive status revealed almost 150 specific alterations in cognitively impaired ALS synaptic preparations. Stratifying by C9ORF72-RE status revealed 330 protein alterations in the C9ORF72-RE&#x2009;+ve group, with KEGG pathway analysis highlighting strong enrichment for postsynaptic dysfunction, related to glutamatergic receptor signalling. We have validated some of these changes by western blot and at a single synapse level using array tomography imaging. In summary, we have generated the first unbiased map of the human ALS synaptic proteome, revealing novel insight into this key compartment in ALS pathophysiology and highlighting the influence of cognitive decline and C9ORF72-RE on synaptic composition.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laszlo</LastName><ForeName>Zsofia I</ForeName><Initials>ZI</Initials><Identifier Source="ORCID">0000-0001-5317-1207</Identifier><AffiliationInfo><Affiliation>Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hindley</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez Avila</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Euan Macdonald Centre, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kline</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>The Euan Macdonald Centre, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Roslin Institute, Royal (Dick) School of Veterinary Studies, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, EH25 9RG, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eaton</LastName><ForeName>Samantha L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>The Roslin Institute, Royal (Dick) School of Veterinary Studies, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, EH25 9RG, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamont</LastName><ForeName>Douglas J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>FingerPrints Proteomics Facility, Discovery Centre, School of Life Sciences, University of Dundee, Dundee, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Euan Macdonald Centre, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Neuropathology, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>The Euan Macdonald Centre, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences and UK Dementia Research Institute at the University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wishart</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>The Euan Macdonald Centre, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Roslin Institute, Royal (Dick) School of Veterinary Studies, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, EH25 9RG, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henstridge</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-0393-180X</Identifier><AffiliationInfo><Affiliation>Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, Scotland, UK. chenstridge@dundee.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Euan Macdonald Centre, Edinburgh, UK. chenstridge@dundee.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">Human brain</Keyword><Keyword MajorTopicYN="N">Proteomics</Keyword><Keyword MajorTopicYN="N">Synapse</Keyword></KeywordList><CoiStatement>The authors declare that they have no Competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>30</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36309735</ArticleId><ArticleId IdType="pmc">PMC9618182</ArticleId><ArticleId IdType="doi">10.1186/s40478-022-01455-z</ArticleId><ArticleId IdType="pii">10.1186/s40478-022-01455-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon YA, Fratta P, Traynor BJ, Chia R. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2020;14:42. doi: 10.3389/fnins.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12(4):368&#x2013;380. doi: 10.1016/S1474-4422(13)70026-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70026-7</ArticleId><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017 doi: 10.1080/21678421.2016.1267768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91(15):e1370&#x2013;e1380. doi: 10.1212/WNL.0000000000006317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Goldstein LH, Kew JJ, Brooks DJ, Lloyd CM, Frith CD, et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study Brain. 1996;119(Pt 6):2105&#x2013;2120.</Citation><ArticleIdList><ArticleId IdType="pubmed">9010014</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1&#x2013;2):9&#x2013;14. doi: 10.3109/21678421.2013.805784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A, Pagani M, Cistaro A, Montuschi A, Iazzolino B, Fania P, et al. 18F-FDG-PET correlates of cognitive impairment in ALS. Neurology. 2016;86(1):44&#x2013;49. doi: 10.1212/WNL.0000000000002242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002242</ArticleId><ArticleId IdType="pubmed">26590270</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RAL, Agosta F, Grosskreutz J, Filippi M, Turner MR. Neuroimaging endpoints in amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14:11&#x2013;23. doi: 10.1007/s13311-016-0484-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0484-9</ArticleId><ArticleId IdType="pmc">PMC5233627</ArticleId><ArticleId IdType="pubmed">27752938</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Agosta F, Bede P, Govind V, Lule D, Verstraete E. Neuroimaging in amyotrophic lateral sclerosis. Biomark Med. 2012;6(3):319&#x2013;337. doi: 10.2217/bmm.12.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm.12.26</ArticleId><ArticleId IdType="pubmed">22731907</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Sideris DI, Carroll E, Rotariu S, Salomonsson S, Tzioras M, et al. Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathol. 2018;135(2):213&#x2013;226. doi: 10.1007/s00401-017-1797-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1797-4</ArticleId><ArticleId IdType="pmc">PMC5773656</ArticleId><ArticleId IdType="pubmed">29273900</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpetti M, Jones PS, Cope TE, Holland N, Naessens M, Rouse MA, et al. (2022) Synaptic loss in behavioural variant frontotemporal dementia revealed by [11C]UCB-J PET. medRxiv. 2022:2022.01.30.22270123</Citation></Reference><Reference><Citation>Fogarty MJ. Driven to decay: excitability and synaptic abnormalities in amyotrophic lateral sclerosis. Brain Res Bull. 2018;140:318&#x2013;333. doi: 10.1016/j.brainresbull.2018.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2018.05.023</ArticleId><ArticleId IdType="pubmed">29870780</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty MJ. Amyotrophic lateral sclerosis as a synaptopathy. Neural Regen Res. 2019;14(2):189&#x2013;192. doi: 10.4103/1673-5374.244782.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.244782</ArticleId><ArticleId IdType="pmc">PMC6301167</ArticleId><ArticleId IdType="pubmed">30530995</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Pickett E, Spires-Jones TL. Synaptic pathology: a shared mechanism in neurological disease. Ageing Res Rev. 2016;28:72&#x2013;84. doi: 10.1016/j.arr.2016.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2016.04.005</ArticleId><ArticleId IdType="pubmed">27108053</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI, et al. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med. 2018;10(1):48&#x2013;62. doi: 10.15252/emmm.201708202.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201708202</ArticleId><ArticleId IdType="pmc">PMC5760858</ArticleId><ArticleId IdType="pubmed">29191947</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, Montal V, Sirisi S, L&#xf3;pez-Pernas G, Cervera-Carles L, Querol-Vilaseca M, et al. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e829. doi: 10.1212/NXI.0000000000000829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000829</ArticleId><ArticleId IdType="pmc">PMC7371375</ArticleId><ArticleId IdType="pubmed">32669313</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasaki S, Xu J, Avey DR, Johnson L, Petyuk VA, Dawe RJ, et al. Inferring protein expression changes from mRNA in alzheimer's dementia using deep neural networks. Nat Commun. 2022;13(1):655. doi: 10.1038/s41467-022-28280-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28280-1</ArticleId><ArticleId IdType="pmc">PMC8814036</ArticleId><ArticleId IdType="pubmed">35115553</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, Carter EK, Dammer EB, Duong DM, Gerasimov ES, Liu Y, et al. Large-scale deep multi-layer analysis of alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nat Neurosci. 2022;25(2):213&#x2013;225. doi: 10.1038/s41593-021-00999-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00999-y</ArticleId><ArticleId IdType="pmc">PMC8825285</ArticleId><ArticleId IdType="pubmed">35115731</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. Diseases WFoNRGoMN El escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven E, Newton J, Foley J, Colville S, Swingler R, Chandran S, et al. Validation of the edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen (ECAS): a cognitive tool for motor disorders. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3&#x2013;4):172&#x2013;179. doi: 10.3109/21678421.2015.1030430.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1030430</ArticleId><ArticleId IdType="pubmed">25967542</ArticleId></ArticleIdList></Reference><Reference><Citation>Black HA, Leighton DJ, Cleary EM, Rose E, Stephenson L, Colville S, et al. Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. Neurobiol Aging. 2017;51:17.e811&#x2013;178.e20. doi: 10.1016/j.neurobiolaging.2016.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.12.013</ArticleId><ArticleId IdType="pmc">PMC5302213</ArticleId><ArticleId IdType="pubmed">28089114</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012;181(4):1426&#x2013;1435. doi: 10.1016/j.ajpath.2012.06.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2012.06.033</ArticleId><ArticleId IdType="pmc">PMC3463637</ArticleId><ArticleId IdType="pubmed">22867711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse R, Hurtado ML, Jackson RJ, Eaton SL, Herrmann AG, Colom-Cadena M, et al. Comparative profiling of the synaptic proteome from Alzheimer's disease patients with focus on the APOE genotype. Acta Neuropathol Commun. 2019;7(1):214. doi: 10.1186/s40478-019-0847-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0847-7</ArticleId><ArticleId IdType="pmc">PMC6925519</ArticleId><ArticleId IdType="pubmed">31862015</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized ppb-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367&#x2013;1372. doi: 10.1038/nbt.1511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1511</ArticleId><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011;10(4):1794&#x2013;1805. doi: 10.1021/pr101065j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr101065j</ArticleId><ArticleId IdType="pubmed">21254760</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham LC, Eaton SL, Brunton PJ, Atrih A, Smith C, Lamont DJ, et al. Proteomic profiling of neuronal mitochondria reveals modulators of synaptic architecture. Mol Neurodegener. 2017;12(1):77. doi: 10.1186/s13024-017-0221-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0221-9</ArticleId><ArticleId IdType="pmc">PMC5659037</ArticleId><ArticleId IdType="pubmed">29078798</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021&#xa0;update) Nucleic Acids Res. 2022 doi: 10.1093/nar/gkac194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac194</ArticleId><ArticleId IdType="pmc">PMC9252805</ArticleId><ArticleId IdType="pubmed">35325185</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44&#x2013;57. doi: 10.1038/nprot.2008.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.211</ArticleId><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay KR, Smith C, Wright AK, Serrano-Pozo A, Pooler AM, Koffie R, et al. Studying synapses in human brain with array tomography and electron microscopy. Nat Protoc. 2013;8(7):1366&#x2013;1380. doi: 10.1038/nprot.2013.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.078</ArticleId><ArticleId IdType="pmc">PMC3712649</ArticleId><ArticleId IdType="pubmed">23787894</ArticleId></ArticleIdList></Reference><Reference><Citation>Thevenaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process. 1998;7(1):27&#x2013;41. doi: 10.1109/83.650848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/83.650848</ArticleId><ArticleId IdType="pubmed">18267377</ArticleId></ArticleIdList></Reference><Reference><Citation>Piehowski PD, Petyuk VA, Orton DJ, Xie F, Moore RJ, Ramirez-Restrepo M, et al. Sources of technical variability in quantitative LC-MS proteomics: human brain tissue sample analysis. J Proteome Res. 2013;12(5):2128&#x2013;2137. doi: 10.1021/pr301146m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr301146m</ArticleId><ArticleId IdType="pmc">PMC3695475</ArticleId><ArticleId IdType="pubmed">23495885</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghamaleky Sarvestany A, Hunter G, Tavendale A, Lamont DJ, Llavero Hurtado M, Graham LC, et al. Label-free quantitative proteomic profiling identifies disruption of ubiquitin homeostasis as a key driver of Schwann cell defects in spinal muscular atrophy. J Proteome Res. 2014;13(11):4546&#x2013;4557. doi: 10.1021/pr500492j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr500492j</ArticleId><ArticleId IdType="pubmed">25151848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillingwater TH, Ingham CA, Parry KE, Wright AK, Haley JE, Wishart TM, et al. Delayed synaptic degeneration in the CNS of Wlds mice after cortical lesion. Brain. 2006;129(Pt 6):1546&#x2013;1556. doi: 10.1093/brain/awl101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl101</ArticleId><ArticleId IdType="pubmed">16738060</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutsaers CA, Lamont DJ, Hunter G, Wishart TM, Gillingwater TH. Label-free proteomics identifies Calreticulin and GRP75/Mortalin as peripherally accessible protein biomarkers for spinal muscular atrophy. Genome Med. 2013;5(10):95. doi: 10.1186/gm498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gm498</ArticleId><ArticleId IdType="pmc">PMC3979019</ArticleId><ArticleId IdType="pubmed">24134804</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche SL, Sherman DL, Dissanayake K, Soucy G, Desmazieres A, Lamont DJ, et al. Loss of glial neurofascin155 delays developmental synapse elimination at the neuromuscular junction. J Neurosci. 2014;34(38):12904&#x2013;12918. doi: 10.1523/JNEUROSCI.1725-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1725-14.2014</ArticleId><ArticleId IdType="pmc">PMC4166168</ArticleId><ArticleId IdType="pubmed">25232125</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlyle BC, Kandigian SE, Kreuzer J, Das S, Trombetta BA, Kuo Y, et al. Synaptic proteins associated with cognitive performance and neuropathology in older humans revealed by multiplexed fractionated proteomics. Neurobiol Aging. 2021;105:99&#x2013;114. doi: 10.1016/j.neurobiolaging.2021.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.04.012</ArticleId><ArticleId IdType="pmc">PMC8338777</ArticleId><ArticleId IdType="pubmed">34052751</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B, Wang X, Li Y, Chen PC, Yu K, Dey KK, et al. Deep multilayer brain proteomics identifies molecular networks in alzheimer's disease progression. Neuron. 2020;105(6):975&#x2013;91.e7. doi: 10.1016/j.neuron.2019.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.12.015</ArticleId><ArticleId IdType="pmc">PMC7318843</ArticleId><ArticleId IdType="pubmed">31926610</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorokina O, Mclean C, Croning MDR, Heil KF, Wysocka E, He X, et al. A unified resource and configurable model of the synapse proteome and its role in disease. Sci Rep. 2021;11(1):9967. doi: 10.1038/s41598-021-88945-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88945-7</ArticleId><ArticleId IdType="pmc">PMC8113277</ArticleId><ArticleId IdType="pubmed">33976238</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopmans F, van Nierop P, Andres-Alonso M, Byrnes A, Cijsouw T, Coba MP, et al. SynGO: an evidence-based, expert-curated knowledge base for the synapse. Neuron. 2019;103(2):217&#x2013;34.e4. doi: 10.1016/j.neuron.2019.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.05.002</ArticleId><ArticleId IdType="pmc">PMC6764089</ArticleId><ArticleId IdType="pubmed">31171447</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirooznia M, Wang T, Avramopoulos D, Valle D, Thomas G, Huganir RL, et al. SynaptomeDB: an ontology-based knowledgebase for synaptic genes. Bioinformatics. 2012;28(6):897&#x2013;899. doi: 10.1093/bioinformatics/bts040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts040</ArticleId><ArticleId IdType="pmc">PMC3307115</ArticleId><ArticleId IdType="pubmed">22285564</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;36(8):2628&#x2013;2629. doi: 10.1093/bioinformatics/btz931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz931</ArticleId><ArticleId IdType="pmc">PMC7178415</ArticleId><ArticleId IdType="pubmed">31882993</ArticleId></ArticleIdList></Reference><Reference><Citation>Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update) Nucleic Acids Res. 2019;47(W1):W191&#x2013;W198. doi: 10.1093/nar/gkz369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz369</ArticleId><ArticleId IdType="pmc">PMC6602461</ArticleId><ArticleId IdType="pubmed">31066453</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, van Vugt JJFA, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636&#x2013;1648. doi: 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD. Trends Genet. 2018;34(6):404&#x2013;423. doi: 10.1016/j.tig.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2018.03.001</ArticleId><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17(1):94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick P, Sellier C, Mackenzie IRA, Cheng CY, Tahraoui-Bories J, Martinat C, et al. Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathol Commun. 2018;6(1):72. doi: 10.1186/s40478-018-0579-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0579-0</ArticleId><ArticleId IdType="pmc">PMC6091050</ArticleId><ArticleId IdType="pubmed">30075745</ArticleId></ArticleIdList></Reference><Reference><Citation>Climer LK, Hendrix RD, Lupashin VV. Conserved oligomeric golgi and neuronal vesicular trafficking. Handb Exp Pharmacol. 2018;245:227&#x2013;247. doi: 10.1007/164_2017_65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/164_2017_65</ArticleId><ArticleId IdType="pmc">PMC6091216</ArticleId><ArticleId IdType="pubmed">29063274</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase G, Rabouille C. Golgi fragmentation in ALS Motor neurons new mechanisms targeting microtubules tethers and transport vesicles. Front Neurosci. 2015;9:448. doi: 10.3389/fnins.2015.00448.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2015.00448</ArticleId><ArticleId IdType="pmc">PMC4672084</ArticleId><ArticleId IdType="pubmed">26696811</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Phukan J, Bede P, Jordan N, Byrne S, Pender N, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. 2011;76(14):1263&#x2013;1269. doi: 10.1212/WNL.0b013e318214359f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318214359f</ArticleId><ArticleId IdType="pubmed">21464431</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap K, Drakew A, Smilovic D, Rietsche M, Paul MH, Vuksic M, et al. The actin-modulating protein synaptopodin mediates long-term survival of dendritic spines. Elife. 2020 doi: 10.7554/eLife.62944.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.62944</ArticleId><ArticleId IdType="pmc">PMC7717903</ArticleId><ArticleId IdType="pubmed">33275099</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137(5):715&#x2013;730. doi: 10.1007/s00401-018-1933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol. 2004;5(10):981&#x2013;986. doi: 10.1038/ni1113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1113</ArticleId><ArticleId IdType="pubmed">15454921</ArticleId></ArticleIdList></Reference><Reference><Citation>Presumey J, Bialas AR, Carroll MC. Complement system in neural synapse elimination in development and disease. Adv Immunol. 2017;135:53&#x2013;79. doi: 10.1016/bs.ai.2017.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ai.2017.06.004</ArticleId><ArticleId IdType="pubmed">28826529</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712&#x2013;716. doi: 10.1126/science.aad8373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Z, Kim E, Ahmed M, Han G, Simmons C, Redhead Y, et al. MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia. Brain Commun. 2021;3(2):fcab114. doi: 10.1093/braincomms/fcab114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab114</ArticleId><ArticleId IdType="pmc">PMC8204366</ArticleId><ArticleId IdType="pubmed">34136812</ArticleId></ArticleIdList></Reference><Reference><Citation>Allodi I, Monta&#xf1;ana-Rosell R, Selvan R, L&#xf6;w P, Kiehn O. Locomotor deficits in a mouse model of ALS are paralleled by loss of V1-interneuron connections onto fast motor neurons. Nat Commun. 2021;12(1):3251. doi: 10.1038/s41467-021-23224-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23224-7</ArticleId><ArticleId IdType="pmc">PMC8166981</ArticleId><ArticleId IdType="pubmed">34059686</ArticleId></ArticleIdList></Reference><Reference><Citation>Maekawa S, Al-Sarraj S, Kibble M, Landau S, Parnavelas J, Cotter D, et al. Cortical selective vulnerability in motor neuron disease: a morphometric study. Brain. 2004;127(Pt 6):1237&#x2013;1251. doi: 10.1093/brain/awh132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh132</ArticleId><ArticleId IdType="pubmed">15130949</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Zaepfel BL, Zarnescu DC. Failure to deliver and translate-new insights into RNA dysregulation in ALS. Front Cell Neurosci. 2017;11:243. doi: 10.3389/fncel.2017.00243.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00243</ArticleId><ArticleId IdType="pmc">PMC5562674</ArticleId><ArticleId IdType="pubmed">28860970</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Bassell GJ, Gitler AD, Hart AC, Klann E, Richter JD, et al. Local RNA translation at the synapse and in disease. J Neurosci. 2011;31(45):16086&#x2013;16093. doi: 10.1523/JNEUROSCI.4105-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4105-11.2011</ArticleId><ArticleId IdType="pmc">PMC3241995</ArticleId><ArticleId IdType="pubmed">22072660</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanzer J, Miyashiro KY, Sul JY, Barrett L, Belt B, Haydon P, et al. RNA splicing capability of live neuronal dendrites. Proc Natl Acad Sci USA. 2005;102(46):16859&#x2013;16864. doi: 10.1073/pnas.0503783102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0503783102</ArticleId><ArticleId IdType="pmc">PMC1277967</ArticleId><ArticleId IdType="pubmed">16275927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603(7899):124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603(7899):131&#x2013;137. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaila K, Price TJ, Payne JA, Puskarjov M, Voipio J. Cation-chloride cotransporters in neuronal development, plasticity and disease. Nat Rev Neurosci. 2014;15(10):637&#x2013;654. doi: 10.1038/nrn3819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3819</ArticleId><ArticleId IdType="pmc">PMC4294553</ArticleId><ArticleId IdType="pubmed">25234263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Bonetto V, Sorar&#xf9; G, Martinelli I, Parchi P, Liguori R, et al. Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Mol Neurodegener. 2020;15(1):58. doi: 10.1186/s13024-020-00406-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00406-3</ArticleId><ArticleId IdType="pmc">PMC7559190</ArticleId><ArticleId IdType="pubmed">33059698</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukkipati SS, Garrett TL, Elbasiouny SM. The vulnerability of spinal motoneurons and soma size plasticity in a mouse model of amyotrophic lateral sclerosis. J Physiol. 2018;596(9):1723&#x2013;1745. doi: 10.1113/JP275498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP275498</ArticleId><ArticleId IdType="pmc">PMC5924829</ArticleId><ArticleId IdType="pubmed">29502344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano SI, Choi EY, Dohi E, Agarwal S, Chang DJ, Wilson AM, et al. Glutathione S-transferases promote proinflammatory astrocyte-microglia communication during brain inflammation. Sci Signal. 2019 doi: 10.1126/scisignal.aar2124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aar2124</ArticleId><ArticleId IdType="pmc">PMC6637164</ArticleId><ArticleId IdType="pubmed">30783009</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadhead MJ, Bonthron C, Waddington J, Smith WV, Lopez MF, Burley S, et al. Selective vulnerability of tripartite synapses in amyotrophic lateral sclerosis. Acta Neuropathol. 2021;212(1):8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8960590</ArticleId><ArticleId IdType="pubmed">35305541</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem. 2007;282(8):5413&#x2013;5419. doi: 10.1074/jbc.M608940200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M608940200</ArticleId><ArticleId IdType="pubmed">17192274</ArticleId></ArticleIdList></Reference><Reference><Citation>Urwyler O, Izadifar A, Vandenbogaerde S, Sachse S, Misbaer A, Schmucker D. Branch-restricted localization of phosphatase Prl-1 specifies axonal synaptogenesis domains. Science. 2019 doi: 10.1126/science.aau9952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aau9952</ArticleId><ArticleId IdType="pubmed">31048465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Hong W. Interorganellar regulation of lysosome positioning by the Golgi apparatus through Rab34 interaction with Rab-interacting lysosomal protein. Mol Biol Cell. 2002;13(12):4317&#x2013;4332. doi: 10.1091/mbc.e02-05-0280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e02-05-0280</ArticleId><ArticleId IdType="pmc">PMC138636</ArticleId><ArticleId IdType="pubmed">12475955</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldenberg NM, Silverman M. Rab34 and its effector munc13-2 constitute a new pathway modulating protein secretion in the cellular response to hyperglycemia. Am J Physiol Cell Physiol. 2009;297(4):C1053&#x2013;C1058. doi: 10.1152/ajpcell.00286.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00286.2009</ArticleId><ArticleId IdType="pubmed">19641095</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasmapour B, Gronow A, Bleck CK, Hong W, Gutierrez MG. Size-dependent mechanism of cargo sorting during lysosome-phagosome fusion is controlled by Rab34. Proc Natl Acad Sci U S A. 2012;109(50):20485&#x2013;20490. doi: 10.1073/pnas.1206811109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206811109</ArticleId><ArticleId IdType="pmc">PMC3528610</ArticleId><ArticleId IdType="pubmed">23197834</ArticleId></ArticleIdList></Reference><Reference><Citation>Varoqueaux F, Sigler A, Rhee JS, Brose N, Enk C, Reim K, et al. Total arrest of spontaneous and evoked synaptic transmission but normal synaptogenesis in the absence of Munc13-mediated vesicle priming. Proc Natl Acad Sci U S A. 2002;99(13):9037&#x2013;9042. doi: 10.1073/pnas.122623799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.122623799</ArticleId><ArticleId IdType="pmc">PMC124419</ArticleId><ArticleId IdType="pubmed">12070347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji YX, Huang Z, Yang X, Wang X, Zhao LP, Wang PX, et al. The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. Nat Med. 2018;24(2):213&#x2013;223. doi: 10.1038/nm.4461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4461</ArticleId><ArticleId IdType="pubmed">29291351</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson-Stone C, Hallupp M, Shahheydari H, Ragagnin AMG, Chatterton Z, Carew-Jones F, et al. CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral sclerosis. Brain. 2020;143(3):783&#x2013;799. doi: 10.1093/brain/awaa039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa039</ArticleId><ArticleId IdType="pmc">PMC7089666</ArticleId><ArticleId IdType="pubmed">32185393</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xe1;buas-Pereira M, Santana I, Kun-Rodrigues C, Bras J, Guerreiro R. CYLD variants in frontotemporal dementia associated with severe memory impairment in a Portuguese cohort. Brain. 2020;143(8):e67. doi: 10.1093/brain/awaa183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa183</ArticleId><ArticleId IdType="pubmed">32666117</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X, Chen Y, Wei Q, Hou Y, Cao B, Zhang L, et al. Rare CYLD variants in chinese patients with amyotrophic lateral sclerosis. Front Genet. 2021;12:740052. doi: 10.3389/fgene.2021.740052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.740052</ArticleId><ArticleId IdType="pmc">PMC8633398</ArticleId><ArticleId IdType="pubmed">34868212</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyston LJ, Chatterton Z, Hallupp M, Rajan N, Kwok JB, Dobson-Stone C. Reply: CYLD variants in frontotemporal dementia associated with severe memory impairment in a Portuguese cohort. Brain. 2020;143(8):e68. doi: 10.1093/brain/awaa184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa184</ArticleId><ArticleId IdType="pmc">PMC7447510</ArticleId><ArticleId IdType="pubmed">32666099</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao MQ, Xie LJ, Leng W, Xue RW. Trim47 is a critical regulator of cerebral ischemia-reperfusion injury through regulating apoptosis and inflammation. Biochem Biophys Res Commun. 2019;515(4):651&#x2013;657. doi: 10.1016/j.bbrc.2019.05.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.05.065</ArticleId><ArticleId IdType="pubmed">31178138</ArticleId></ArticleIdList></Reference><Reference><Citation>Putkey JA, Waxham MN, Gaertner TR, Brewer KJ, Goldsmith M, Kubota Y, et al. Acidic/IQ motif regulator of calmodulin. J Biol Chem. 2008;283(3):1401&#x2013;1410. doi: 10.1074/jbc.M703831200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M703831200</ArticleId><ArticleId IdType="pmc">PMC3617039</ArticleId><ArticleId IdType="pubmed">17991744</ArticleId></ArticleIdList></Reference><Reference><Citation>Utal AK, Stopka AL, Roy M, Coleman PD. PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington's disease. Neuroscience. 1998;86(4):1055&#x2013;1063. doi: 10.1016/S0306-4522(98)00130-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(98)00130-4</ArticleId><ArticleId IdType="pubmed">9697113</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei P, Blundon JA, Rong Y, Zakharenko SS, Morgan JI. Impaired locomotor learning and altered cerebellar synaptic plasticity in pep-19/PCP4-null mice. Mol Cell Biol. 2011;31(14):2838&#x2013;2844. doi: 10.1128/MCB.05208-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.05208-11</ArticleId><ArticleId IdType="pmc">PMC3133400</ArticleId><ArticleId IdType="pubmed">21576365</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa JM, Farr&#xe9;-Alins V, Ortega MC, Navarrete M, Lopez-Rodriguez AB, Palomino-Antol&#xed;n A, et al. TLR4 pathway impairs synaptic number and cerebrovascular functions through astrocyte activation following traumatic brain injury. Br J Pharmacol. 2021;178(17):3395&#x2013;3413. doi: 10.1111/bph.15488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15488</ArticleId><ArticleId IdType="pmc">PMC8453872</ArticleId><ArticleId IdType="pubmed">33830504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Lee JD, Phipps S, Noakes PG, Woodruff TM. Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2015;12:90. doi: 10.1186/s12974-015-0310-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0310-z</ArticleId><ArticleId IdType="pmc">PMC4431460</ArticleId><ArticleId IdType="pubmed">25962427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro P, Castro MV, Perez M, Cartarozzi LP, Spejo AB, Chiarotto GB, et al. Toll-like receptor 4 (TLR4) influences the glial reaction in the spinal cord and the neural response to injury following peripheral nerve crush. Brain Res Bull. 2020;155:67&#x2013;80. doi: 10.1016/j.brainresbull.2019.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2019.11.008</ArticleId><ArticleId IdType="pubmed">31756421</ArticleId></ArticleIdList></Reference><Reference><Citation>DaRosa PA, Wang Z, Jiang X, Pruneda JN, Cong F, Klevit RE, et al. Allosteric activation of the RNF146 ubiquitin ligase by a poly(ADP-ribosyl)ation signal. Nature. 2015;517(7533):223&#x2013;226. doi: 10.1038/nature13826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13826</ArticleId><ArticleId IdType="pmc">PMC4289021</ArticleId><ArticleId IdType="pubmed">25327252</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DS, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med. 2021;53(1):42&#x2013;51. doi: 10.1038/s12276-021-00557-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00557-3</ArticleId><ArticleId IdType="pmc">PMC8080675</ArticleId><ArticleId IdType="pubmed">33487630</ArticleId></ArticleIdList></Reference><Reference><Citation>David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci (Landmark Ed) 2009;14(3):1116&#x2013;1128. doi: 10.2741/3297.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/3297</ArticleId><ArticleId IdType="pmc">PMC4450718</ArticleId><ArticleId IdType="pubmed">19273119</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L, Mojsilovic-Petrovic J, Van Deerlin VM, Shorter J, Kalb RG, Lee VM, et al. Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2018;6(1):84. doi: 10.1186/s40478-018-0586-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0586-1</ArticleId><ArticleId IdType="pmc">PMC6114235</ArticleId><ArticleId IdType="pubmed">30157956</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L, Rifai OM, Bonini NM. Poly(ADP-Ribosylation) in age-related neurological disease. Trends Genet. 2019;35(8):601&#x2013;613. doi: 10.1016/j.tig.2019.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2019.05.004</ArticleId><ArticleId IdType="pmc">PMC6625889</ArticleId><ArticleId IdType="pubmed">31182245</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrabi SA, Kang HC, Haince JF, Lee YI, Zhang J, Chi Z, et al. Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nat Med. 2011;17(6):692&#x2013;699. doi: 10.1038/nm.2387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2387</ArticleId><ArticleId IdType="pmc">PMC3709257</ArticleId><ArticleId IdType="pubmed">21602803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HW, Choi J, Shin H, Kim K, Yang J, Na M, et al. Preso, a novel PSD-95-interacting FERM and PDZ domain protein that regulates dendritic spine morphogenesis. J Neurosci. 2008;28(53):14546&#x2013;14556. doi: 10.1523/JNEUROSCI.3112-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3112-08.2008</ArticleId><ArticleId IdType="pmc">PMC6671232</ArticleId><ArticleId IdType="pubmed">19118189</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu JH, Yang L, Kammermeier PJ, Moore CG, Brakeman PR, Tu J, et al. Preso1 dynamically regulates group I metabotropic glutamate receptors. Nat Neurosci. 2012;15(6):836&#x2013;844. doi: 10.1038/nn.3103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3103</ArticleId><ArticleId IdType="pmc">PMC3434267</ArticleId><ArticleId IdType="pubmed">22561452</ArticleId></ArticleIdList></Reference><Reference><Citation>Piard J, Hu JH, Campeau PM, Rzonca S, Van Esch H, Vincent E, et al. FRMPD4 mutations cause X-linked intellectual disability and disrupt dendritic spine morphogenesis. Hum Mol Genet. 2018;27(4):589&#x2013;600. doi: 10.1093/hmg/ddx426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx426</ArticleId><ArticleId IdType="pmc">PMC5886117</ArticleId><ArticleId IdType="pubmed">29267967</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Gelpi E, Povedano M, Santpere G, Ferrer I. Gene expression profile in frontal cortex in sporadic frontotemporal lobar degeneration-TDP. J Neuropathol Exp Neurol. 2018;77(7):608&#x2013;627. doi: 10.1093/jnen/nly037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nly037</ArticleId><ArticleId IdType="pubmed">29788265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, McDonald TS, Fung JNT, Woodruff TM. Absence of receptor for advanced glycation end product (RAGE) reduces inflammation and extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. Mol Neurobiol. 2020;57(10):4143&#x2013;4155. doi: 10.1007/s12035-020-02019-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02019-9</ArticleId><ArticleId IdType="pubmed">32676989</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean M, Juranek J, Cuddapah S, L&#xf3;pez-D&#xed;ez R, Ruiz HH, Hu J, et al. Microglia RAGE exacerbates the progression of neurodegeneration within the SOD1 G93A murine model of amyotrophic lateral sclerosis in a sex-dependent manner. J Neuroinflamm. 2021;18(1):139. doi: 10.1186/s12974-021-02191-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02191-2</ArticleId><ArticleId IdType="pmc">PMC8207569</ArticleId><ArticleId IdType="pubmed">34130712</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Rabiner EA, Hammers A, Al-Chalabi A, Grasby PM, Shaw CE, et al. [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain. 2005;128(Pt 4):896&#x2013;905. doi: 10.1093/brain/awh428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh428</ArticleId><ArticleId IdType="pubmed">15689356</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018;14(9):544&#x2013;558. doi: 10.1038/s41582-018-0047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Pan YE, Giacomotto J, Patten SA. Reduced C9orf72 function leads to defective synaptic vesicle release and neuromuscular dysfunction in zebrafish. Commun Biol. 2021;4(1):792. doi: 10.1038/s42003-021-02302-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02302-y</ArticleId><ArticleId IdType="pmc">PMC8233344</ArticleId><ArticleId IdType="pubmed">34172817</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen BK, Schuldi MH, McAvoy K, Russell KA, Boehringer A, Curran BM, et al. Synaptic dysfunction induced by glycine-alanine dipeptides in C9orf72-ALS/FTD is rescued by SV2 replenishment. EMBO Mol Med. 2020;12(5):e10722. doi: 10.15252/emmm.201910722.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201910722</ArticleId><ArticleId IdType="pmc">PMC7207170</ArticleId><ArticleId IdType="pubmed">32347002</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins EM, Burr K, Banerjee P, Mehta AR, Dando O, Selvaraj BT, et al. Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction. Mol Neurodegener. 2021;16(1):13. doi: 10.1186/s13024-021-00433-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00433-8</ArticleId><ArticleId IdType="pmc">PMC7931347</ArticleId><ArticleId IdType="pubmed">33663561</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanese A, Rajkumar S, Sommer D, Freisem D, Wirth A, Aly A, et al. Synaptic disruption and CREB-regulated transcription are restored by K. EMBO Mol Med. 2021;13(7):e13131. doi: 10.15252/emmm.202013131.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202013131</ArticleId><ArticleId IdType="pmc">PMC8261490</ArticleId><ArticleId IdType="pubmed">34125498</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr A, Sattler R. Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD. Brain Res. 2018;1693(Pt A):98&#x2013;108. doi: 10.1016/j.brainres.2018.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.02.011</ArticleId><ArticleId IdType="pmc">PMC5997509</ArticleId><ArticleId IdType="pubmed">29453960</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizzardo M, Taiana M, Rizzo F, Aguila Benitez J, Nijssen J, Allodi I, et al. Synaptotagmin 13 is neuroprotective across motor neuron diseases. Acta Neuropathol. 2020;139(5):837&#x2013;853. doi: 10.1007/s00401-020-02133-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02133-x</ArticleId><ArticleId IdType="pmc">PMC7181443</ArticleId><ArticleId IdType="pubmed">32065260</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricker LD, McKinzie AA, Sun J, Curran E, Qian Y, Yan L, et al. Identification and characterization of proSAAS, a granin-like neuroendocrine peptide precursor that inhibits prohormone processing. J Neurosci. 2000;20(2):639&#x2013;648. doi: 10.1523/JNEUROSCI.20-02-00639.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-02-00639.2000</ArticleId><ArticleId IdType="pmc">PMC6772395</ArticleId><ArticleId IdType="pubmed">10632593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi K, Arawaka S, Koyama S, Kimura H, Ren CH, Wada M, et al. An N-terminal fragment of ProSAAS (a granin-like neuroendocrine peptide precursor) is associated with tau inclusions in Pick's disease. Biochem Biophys Res Commun. 2003;308(3):646&#x2013;654. doi: 10.1016/S0006-291X(03)01391-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(03)01391-3</ArticleId><ArticleId IdType="pubmed">12914799</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada M, Ren CH, Koyama S, Arawaka S, Kawakatsu S, Kimura H, et al. A human granin-like neuroendocrine peptide precursor (proSAAS) immunoreactivity in tau inclusions of Alzheimer's disease and parkinsonism-dementia complex on Guam. Neurosci Lett. 2004;356(1):49&#x2013;52. doi: 10.1016/j.neulet.2003.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2003.11.028</ArticleId><ArticleId IdType="pubmed">14746899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahn H, Wittke S, Z&#xfc;rbig P, Raedler TJ, Arlt S, Kellmann M, et al. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One. 2011;6(10):e26540. doi: 10.1371/journal.pone.0026540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026540</ArticleId><ArticleId IdType="pmc">PMC3202544</ArticleId><ArticleId IdType="pubmed">22046305</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidsson P, Sj&#xf6;gren M, Andreasen N, Lindbjer M, Nilsson CL, Westman-Brinkmalm A, et al. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res. 2002;109(1&#x2013;2):128&#x2013;133. doi: 10.1016/S0169-328X(02)00549-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(02)00549-1</ArticleId><ArticleId IdType="pubmed">12531522</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino A, Helwig M, Rezaei S, Berridge C, Eriksen JL, Lindberg I. A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease. J Neurochem. 2014;128(3):419&#x2013;430. doi: 10.1111/jnc.12454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12454</ArticleId><ArticleId IdType="pmc">PMC3946950</ArticleId><ArticleId IdType="pubmed">24102330</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvela TS, Lam HA, Helwig M, Lorenzen N, Otzen DE, McLean PJ, et al. The neural chaperone proSAAS blocks &#x3b1;-synuclein fibrillation and neurotoxicity. Proc Natl Acad Sci U S A. 2016;113(32):E4708&#x2013;E4715. doi: 10.1073/pnas.1601091113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1601091113</ArticleId><ArticleId IdType="pmc">PMC4987805</ArticleId><ArticleId IdType="pubmed">27457957</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163(1):123&#x2013;133. doi: 10.1016/j.cell.2015.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.09.015</ArticleId><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Taylor JP. The role of dipeptide repeats in C9ORF72-related ALS-FTD. Front Mol Neurosci. 2017;10:35. doi: 10.3389/fnmol.2017.00035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00035</ArticleId><ArticleId IdType="pmc">PMC5303742</ArticleId><ArticleId IdType="pubmed">28243191</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Zheng Y, Murphy K, Huang M, Hu F. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet. 2013;22(4):685&#x2013;695. doi: 10.1093/hmg/dds475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds475</ArticleId><ArticleId IdType="pmc">PMC3554197</ArticleId><ArticleId IdType="pubmed">23136129</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010;42(3):234&#x2013;239. doi: 10.1038/ng.536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.536</ArticleId><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol. 2014;127(3):407&#x2013;418. doi: 10.1007/s00401-013-1239-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1239-x</ArticleId><ArticleId IdType="pmc">PMC4003885</ArticleId><ArticleId IdType="pubmed">24442578</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, et al. Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related phenotypes in progranulin-deficient mice. Neuron. 2017;95(2):281&#x2013;96.e6. doi: 10.1016/j.neuron.2017.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.06.026</ArticleId><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang YX, Cao Q, Sawaya MR, Abskharon R, Ge P, DeTure M, et al. Amyloid fibrils in disease FTLD-TDP are composed of TMEM106B not TDP-43. Nature. 2022 doi: 10.1038/s41586-022-04670-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04670-9</ArticleId><ArticleId IdType="pubmed">35344984</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk BM, Lang CM, Hogl S, Tahirovic S, Orozco D, Rentzsch K, et al. The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. EMBO J. 2014;33(5):450&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989627</ArticleId><ArticleId IdType="pubmed">24357581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>